Immunotherapy in neuroendocrine tumors 1 - current available therapy options

Published on January 30, 2017   18 min

Other Talks in the Series: Immunotherapy of Cancer

0:00
So thank you for the opportunity to speak today. My name is Nitya Raj. I am one of the Assistant Attending Physicians in the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. My clinical practice is devoted to the care of patients with gastrointestinal cancers, particularly neuroendocrine tumors. And I'm a clinical researcher who focuses my research activities on identifying new therapies for patients with neuroendocrine tumors. In addition, I'm also studying ways to improve our understanding of the tumor biology of this rare group of cancers, particularly understanding how neuroendocrine tumors change genetically over time and as a result of different treatments. So today, I'm going to be speaking to you about immunotherapy in neuroendocrine tumors.
0:51
Okay, so here is the agenda that we'll be focusing on today. First, I'm going to give a brief background on neuroendocrine tumors. I'll then highlight our current therapy options that are available as of 2016. I'll move on to then discuss what has already been done to evaluate for a role of immunotherapy, and I'm going to take us back to what's been done previously both in the clinic and in the lab, and I'll conclude the talk by discussing where we can go from here and how we can use the data we already have to develop clinical trials for immunotherapy in neuroendocrine tumors.
Hide

Immunotherapy in neuroendocrine tumors 1 - current available therapy options

Embed in course/own notes